The management of Leishmania donova ni (LD), responsible for fatal visceral leishmaniasis (VL), faces increasing challenges due to rising drug-unresponsiveness, leading to increasing treatment ...
Johnson & Johnson has moved a step closer to filing a potential first-in-class therapy for psoriasis after the drug hit the mark in a phase 3 trial. Once-daily oral IL-23 inhibitor icotrokinra (fo ...
After hours: February 7 at 6:42:18 PM EST Loading Chart for MRKR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback